Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Immunai has raised €18M across 1 funding round from 2 investors, most recently a Seed round in May 2020. Based in New York, United States; founded 2019; active in AI. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-05-14 | Seed | €18M |
| TLV Partners,Viola Group |
| View deal → |
